Anthony Fauci, whos a director of the US National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, which co-developed a drug with the London, England-based drug company GlaxoSmithKline in the United Kingdom added two lines, All in all, I would say it was a successful phase-1 study, The next step are to move ahead with a larger efficacy trial in West Africa. The vaccines are similar to one thats on track to be tested in larger trials in western Africa are likely begin early next year. In these phase-2 and phase-3 trials, about thousands of people who are at risk of contracting the virus, such as health workers, will receive the vaccine to determine whether it can protect against infection. The vaccine that has been tested in the United States was made from a cold-causing chimpanzee adenovirus that had been engineered to express proteins from two species of the Ebola virus, known as Zaire and Sudan, and that was already available when the trial began in early September. With the antibody action, only an efficacy trial involving people at risk of infection can reveal whether a vaccine prevents infection: But the levels of antibodies that the high-dose volunteers generated were in line with those seen in monkeys that were protected from Ebola after receiving the same vaccine Anthony Fauci interpreted.
Posted on: Wed, 03 Dec 2014 21:12:11 +0000
Trending Topics
Recently Viewed Topics
© 2015